PMID- 23726601
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20181202
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - A Japanese multicenter study of high-dose mizoribine combined with cyclosporine, 
      basiliximab, and corticosteroid in renal transplantation (the fourth report).
PG  - 1476-80
LID - S0041-1345(13)00321-7 [pii]
LID - 10.1016/j.transproceed.2013.03.016 [doi]
AB  - We examined the efficacy and safety of 4-drug combination therapy using high-dose 
      mizoribine (MZR) (8 mg/kg/d), cyclosporine (CsA), basiliximab (BXM), and steroid 
      (STR) in 39 renal transplant recipients. Acute rejection episodes (ARE), which 
      occurred in 9 (23.1%) patients, correlated with lower blood levels of MZR (trough 
      levels >/= 2 mug/mL). In addition, lower MZR concentrations tended to be associated 
      with a higher incidence of rejection episodes in children aged </= 10 years than in 
      those aged >/= 11 years. The area under the received operating characteristics 
      (ROC) curve of MZR trough level to pred ARE was 0.825 (95% confidence interval, 
      0.690-0.962; P = .002). Based on the ROC analysis, are MZR cut-off of 1.6 mug/mL 
      showed a sensitivity of 81.8% and a specificity of 75.0%. Adverse events were 
      observed in 23 patients, including infections in 11 (7 patients positive for 
      cytomegalovirus [CMV] antigen and 4 treated with anti-CMV drugs). The MZR trough 
      levels seemed to be higher among patients with adverse events than in those free 
      of them, but it was no significant. All patients experienced successful 
      engraftment except 1 who died of unknown cause with a functioning graft. In 
      conclusion, our study showed that low MZR trough levels correlated with the 
      incidence of ARE. No serious adverse effects were encountered with this therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Oshiro, Y
AU  - Oshiro Y
AD  - Faculty of Medicine, University of the Ryukyus, Urology, Nishihara, Okinawa, 
      Japan. yoshi43@med.u-ryukyu.ac.jp
FAU - Nakagawa, K
AU  - Nakagawa K
FAU - Hoshinaga, K
AU  - Hoshinaga K
FAU - Aikawa, A
AU  - Aikawa A
FAU - Shishido, S
AU  - Shishido S
FAU - Yoshida, K
AU  - Yoshida K
FAU - Asano, T
AU  - Asano T
FAU - Murai, M
AU  - Murai M
FAU - Hasegawa, A
AU  - Hasegawa A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Ribonucleosides)
RN  - 4JR41A10VP (mizoribine)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 9927MT646M (Basiliximab)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/*administration & dosage
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Basiliximab
MH  - Child
MH  - Child, Preschool
MH  - Cyclosporine/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Japan
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Ribonucleosides/*administration & dosage
MH  - Young Adult
EDAT- 2013/06/04 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/14 00:00 [received]
PHST- 2013/02/16 00:00 [revised]
PHST- 2013/03/04 00:00 [accepted]
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - S0041-1345(13)00321-7 [pii]
AID - 10.1016/j.transproceed.2013.03.016 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1476-80. doi: 10.1016/j.transproceed.2013.03.016.